



Date: November 21, 2019

Re: New Prescription Drug Notice from Novo Nordisk Inc. - Rybelsus® Oral Tablet

Submitted via e-mail: [AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov)

To the Vermont Attorney General Office,

On October 24, 2019, Novo Nordisk Inc. submitted notice of a new prescription drug to market from Novo Nordisk Inc. for Rybelsus Oral Tablet. Pursuant to 18.V.S.A § 4637 (c), Novo Nordisk Inc. is providing the additional information:

<b>NDC</b>	00169430313	00169430713	00169431413
<b>Drug Product Description</b>	Rybelsus® Oral Tablet 3mg	Rybelsus® Oral Tablet 7mg	Rybelsus® Oral Tablet 14mg
<b>Introduced to Market Date</b>	10/22/2019	10/22/2019	10/22/2019
<b>WAC at Intro to Market</b>	\$772.43	\$772.43	\$772.43
<b>Marketing &amp; Pricing Plan</b>	Marketing & Pricing Plan is not publicly available information.		
<b>Estimated Volume of Patients</b>	1,400,000	1,400,000	1,400,000
	RYBELSUS® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The estimated patients figure is based on the total estimated number of patients in the United States who utilize GLP-1 RA therapies and therefore are likely candidates for RYBELSUS®. It is not an estimate of prescriptions that might be written for each available dose of RYBELSUS®. RYBELSUS® will represent a portion of the broader market for GLP-1 RA therapies.		
<b>Breakthrough therapy?</b>	No	No	No
<b>Priority Review?</b>	Yes	Yes	Yes
<b>Acquisition Date</b>	N/A	N/A	N/A
<b>Acquisition Price</b>	N/A	N/A	N/A